NYSE:JNJPharmaceuticals
Did New IMAAVY Data in Myasthenia Gravis Just Shift Johnson & Johnson's (JNJ) Investment Narrative?
Earlier this week, Johnson & Johnson reported long-term Phase 3 Vivacity-MG3 and open-label extension data for IMAAVY (nipocalimab-aahu) in generalized myasthenia gravis, showing sustained disease control, quality-of-life gains, and meaningful IgG reductions over 120 weeks while also progressing a head-to-head FcRn blocker study.
This reinforces Johnson & Johnson’s Innovative Medicine pipeline in immunology, underlining how new specialty therapies could help offset pressure from older drugs...